Uteroglobin in the treatment of iga mediated autoimmune disorders
CA 2370738 C · Owner: The Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services · Inventors: Mukherjee, Anil B.; Zheng, Feng; Zhang, Zhongjian
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
Uteroglobin has been discovered to prevent IgA mediated diseases such as IgA , nephropathy, by preventing the deposition of IgA-Fibronectin immunocomplexes in tissues such as the renal glomeruli. The invention therefore includes methods of treating such diseases by administering therapeutically effective amounts of uteroglobin (and variants or mimetics) to prevent or improve the IgA mediated condition. Transgenic uteroglobin knockout animals and animals , in which uteroglobin-protein expression is reduced by antisense technology also provide systems for studying IgA mediated diseases and screening for , appropriate treatments.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed April 13, 2000 and granted August 9, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended April 13, 2020.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by April 13, 2022.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.